Reaction
Bladder Neoplasm reporting signals
As of the last recalculation, Bladder Neoplasm appears in 1,693 FAERS reports alongside 21 co-occurring drug terms. The strongest observed disproportionality signal is PIOGLITAZONE (PRR 23.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pioglitazone | 80 | 23.8 | 23.9 |
| Botulinum Toxin Type A | 15 | 15.0 | 15.0 |
| Dutasteride | 7 | 10.6 | 10.6 |
| Febuxostat Tablets 40 Mg | 7 | 8.5 | 8.5 |
| Febuxostat Tablets 80 Mg | 7 | 8.5 | 8.5 |
| Pitavastatin Calcium | 7 | 8.4 | 8.4 |
| Bicalutamide | 10 | 8.1 | 8.1 |
| Leuprolide Acetate | 44 | 7.1 | 7.1 |
| Polatuzumab Vedotin | 5 | 6.3 | 6.3 |
| Abiraterone | 6 | 5.4 | 5.4 |
| Ibrutinib | 30 | 4.6 | 4.6 |
| Obinutuzumab | 6 | 4.5 | 4.5 |
| Abiraterone Acetate | 14 | 4.2 | 4.2 |
| Apalutamide | 4 | 4.2 | 4.2 |
| Tafamidis | 4 | 4.2 | 4.2 |
| Lutetium Lu 177 Vipivotide Tetraxetan | 4 | 3.7 | 3.7 |
| Ranitidine Hydrochloride | 16 | 3.6 | 3.6 |
| Ambrisentan | 33 | 3.3 | 3.3 |
| Sofosbuvir | 5 | 3.1 | 3.1 |
| Enzalutamide | 14 | 2.9 | 2.9 |
| Orlistat | 5 | 2.4 | 2.4 |